8-K: Accuray Reports Fiscal 2025 Third Quarter Financial Results, Reaffirms Adjusted EBITDA Guidance

Accuray Incorporated announced its Q3 fiscal year 2025 financial results, showcasing revenue growth and improved profitability despite evolving global dynamics.

Summary

• Accuray Incorporated reported its financial results for the third quarter ended March 31, 2025.
• Total net revenue for the quarter was $113.2 million, a 12% increase year-over-year.
• The company's net loss decreased to $1.3 million, compared to a $6.3 million loss in the same period last year.
• Adjusted EBITDA improved significantly to $6.0 million from $1.1 million in the prior year period.
• Product revenue increased by 16% to $57.3 million, while service revenue rose by 9% to $55.9 million.
• Gross product orders decreased to $71.2 million from $89.1 million in the prior year.
• The book-to-bill ratio was 1.2, compared to 1.8 in the prior year.
• Order backlog as of March 31, 2025, was $452.4 million, approximately 10% lower than the previous year.
• Cash, cash equivalents, and short-term restricted cash totaled $78.8 million.
• For the first nine months of fiscal 2025, total net revenue increased by 6% to $331.0 million.
• The company reaffirmed its adjusted EBITDA guidance for fiscal year 2025, expecting it to be in the range of $28.5 million to $31.0 million.
• Revenue guidance for fiscal year 2025 was adjusted to a range of $452 million to $460 million due to recent tariff announcements.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth, improved profitability, and reaffirmed EBITDA guidance, but tempered by decreased gross orders and a reduced revenue outlook due to tariffs.

Positives

• Total net revenue increased by 12% year-over-year in Q3 2025.
• Net loss significantly decreased from $6.3 million to $1.3 million in Q3 2025.
• Adjusted EBITDA improved substantially to $6.0 million in Q3 2025.
• Product and service revenues both showed growth, with product revenue increasing by 16% and service revenue by 9%.
• Operating expenses decreased by 9% in Q3 2025.
• Cash position improved by $14.8 million compared to the previous quarter.

Negatives

• Gross product orders decreased to $71.2 million from $89.1 million in the prior year.
• Order backlog decreased by approximately 10% compared to the prior fiscal year.
• Revenue guidance for fiscal year 2025 was adjusted downwards due to tariff impacts.

Risks

• The company faces risks related to the global macroeconomic environment and its impact on operations.
• Disruptions to the supply chain, including increased logistics costs, pose a risk.
• The company's ability to achieve widespread market acceptance of its products is uncertain.
• International tariffs could negatively affect the company's financial results.
• The company's ability to convert backlog to revenue is a potential risk factor.
• The company's ability to refinance its debt is a potential risk factor.

Future Outlook

Accuray reaffirmed its adjusted EBITDA guidance for fiscal year 2025, expecting it to be in the range of $28.5 million to $31.0 million. Total revenue is expected in the range of $452 million to $460 million.

Management Comments

• Suzanne Winter, CEO of Accuray, stated that the company's disciplined execution, clear strategy, and growing demand for its technologies give them confidence in their ability to deliver sustained performance.

Industry Context

Accuray operates in the radiation therapy market, which is characterized by technological advancements and increasing demand for cancer treatment solutions. The company's performance is influenced by factors such as global healthcare spending, regulatory approvals, and competition from other medical device manufacturers.

Comparison to Industry Standards

• Accuray's revenue growth of 12% in Q3 2025 is a positive sign, but it's important to compare this to the growth rates of competitors like Varian Medical Systems (now part of Siemens Healthineers) and Elekta.
• The adjusted EBITDA margin of Accuray in Q3 2025 is 5.3% ($6.0 million/$113.2 million).
• The decrease in gross product orders and order backlog is a concern and should be monitored closely against industry trends and competitor performance.
• Accuray's focus on expanding patient access to radiotherapy treatments aligns with the broader industry goal of improving cancer care outcomes.

Stakeholder Impact

• Shareholders will likely react positively to the improved financial performance and reaffirmed EBITDA guidance.
• Employees may be encouraged by the company's growth and profitability.
• Customers can expect continued innovation and support from Accuray.
• Suppliers may benefit from the company's increased revenue and production.

Next Steps

• Accuray will host a conference call to discuss the results for the third quarter of fiscal 2025.
• The company will continue to focus on executing its strategies and navigating global challenges.
• Accuray will monitor the impact of tariffs and adjust its operations accordingly.

Key Dates

Keywords

Accuray, Financial Results, Radiation Therapy, Adjusted EBITDA, Revenue, Fiscal Year 2025, Net Loss, Product Revenue, Service Revenue